Organon (OGN) Liabilities and Shareholders Equity (2020 - 2025)
Organon has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $12.9 billion for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $12.9 billion for Q4 2025, down 1.79% from a year ago — trailing twelve months through Dec 2025 was $53.1 billion (up 6.37% YoY), and the annual figure for FY2025 was $12.9 billion, down 1.79%.
- Liabilities and Shareholders Equity for Q4 2025 was $12.9 billion at Organon, down from $13.6 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for OGN hit a ceiling of $13.6 billion in Q3 2025 and a floor of $9.6 billion in Q1 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $11.2 billion (2021), compared with a mean of $11.6 billion.
- Biggest five-year swings in Liabilities and Shareholders Equity: dropped 7.92% in 2022 and later grew 15.8% in 2024.
- Organon's Liabilities and Shareholders Equity stood at $10.7 billion in 2021, then rose by 2.57% to $11.0 billion in 2022, then grew by 10.07% to $12.1 billion in 2023, then increased by 8.65% to $13.1 billion in 2024, then decreased by 1.79% to $12.9 billion in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $12.9 billion (Q4 2025), $13.6 billion (Q3 2025), and $13.5 billion (Q2 2025) per Business Quant data.